GSK CEO Emma Walmsley's Shareholding Notified
Ticker: GLAXF · Form: 6-K · Filed: Jul 18, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Key Dollar Amounts | $38.7368 |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, executive-disclosure, sec-filing
TL;DR
GSK CEO Emma Walmsley's stock moves are public record, check the 6-K.
AI Summary
GSK plc filed a Form 6-K on July 18, 2024, reporting a transaction notification regarding director and PDMR shareholding. Specifically, it details shareholding information for Emma Walmsley, the Chief Executive Officer, in accordance with regulatory requirements.
Why It Matters
This filing provides transparency into the shareholdings of key executives, which can be an indicator of insider confidence in the company's performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of executive shareholding information, not indicative of significant company risk.
Key Players & Entities
- GSK plc (company) — Registrant
- Emma Walmsley (person) — Chief Executive Officer
- July 18, 2024 (date) — Filing date
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Who is the primary individual whose shareholding is being notified?
The primary individual is Emma Walmsley, the Chief Executive Officer of GSK plc.
What is the company's principal executive office address?
The company's principal executive office is located at 980 Great West Road, Brentford, Middlesex, TW8 9GS.
What is the Commission File Number for GSK plc?
The Commission File Number for GSK plc is 001-15170.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Stats: 2,876 words · 12 min read · ~10 pages · Grade level 17.1 · Accepted 2024-07-18 11:53:17
Key Financial Figures
- $38.7368 —   Volume(s)     $38.7368   2,859.199    
Filing Documents
- a9947w.htm (6-K) — 319KB
- 0001654954-24-009091.txt ( ) — 320KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: July 18, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc